Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results